Jacobs Levy Equity Management’s Pacira BioSciences PCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.25M	Buy	188,186 +17,711	+10%	+$394K	0.02%	449
2025 Q4	$4.41M	Sell	170,475 -482,105	-74%	-$11.5M	0.02%	433
2025 Q3	$16.8M	Sell	652,580 -332,162	-34%	-$8.16M	0.07%	223
2025 Q2	$23.5M	Buy	984,742 +129,254	+15%	+$3.26M	0.09%	195
2025 Q1	$21.3M	Buy	855,488 +401,227	+88%	+$9.61M	0.08%	217
2024 Q4	$8.56M	Buy	+454,261	New	+$7.98M	0.03%	327
2021 Q1	–	Sell	-55,041	Closed	-$3.29M	–	1098
2020 Q4	$3.29M	Sell	55,041 -4,723	-8%	-$277K	0.03%	476
2020 Q3	$3.59M	Sell	59,764 -162,531	-73%	-$9.44M	0.04%	415
2020 Q2	$11.7M	Sell	222,295 -20,882	-9%	-$873K	0.13%	189
2020 Q1	$8.15M	Buy	243,177 +418	+0.2%	+$17.4K	0.1%	209
2019 Q4	$11M	Buy	242,759 +46,660	+24%	+$1.98M	0.11%	225
2019 Q3	$7.46M	Buy	196,099 +12,000	+7%	+$479K	0.09%	263
2019 Q2	$8.01M	Buy	184,099 +13,660	+8%	+$580K	0.11%	244
2019 Q1	$6.49M	Buy	170,439 +71,150	+72%	+$2.78M	0.09%	282
2018 Q4	$4.27M	Buy	+99,289	New	+$4.63M	0.08%	297
2017 Q4	–	Sell	-7,280	Closed	-$273K	–	1046
2017 Q3	$273K	Buy	+7,280	New	+$293K	0.01%	806